Cargando…

Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

BACKGROUND: Trials of tyrosine kinase inhibitors (TKI) have not demonstrated dramatic benefits in advanced colorectal cancer (CRC), and this may be a function of poor patient selection. TKI‐induced hypertension is reportedly a surrogate marker for treatment benefit for some tumor types. Our objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rattner, Jodi I., Kopciuk, Karen A., Vogel, Hans J., Tang, Patricia A., Shapiro, Jeremy D., Tu, Dongsheng, Jonker, Derek J., Siu, Lillian L., O'Callaghan, Chris J., Bathe, Oliver F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469666/ https://www.ncbi.nlm.nih.gov/pubmed/37329221 http://dx.doi.org/10.1002/cam4.6248

Ejemplares similares

Early detection of treatment futility in patients with metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2022)

A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome
por: Amin, Shahil, et al.
Publicado: (2019)

Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach
por: Rattner, Jodi, et al.
Publicado: (2017)

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
por: Jones, Robin L., et al.
Publicado: (2019)

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

A Framework for Development of Useful Metabolomic Biomarkers and Their Effective Knowledge Translation
por: Marchand, Calena R., et al.
Publicado: (2018)

Brivanib in combination with Notch3 silencing shows potent activity in tumour models
por: Giovannini, Catia, et al.
Publicado: (2019)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics
por: Farshidfar, Farshad, et al.
Publicado: (2016)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

A quantitative multimodal metabolomic assay for colorectal cancer
por: Farshidfar, Farshad, et al.
Publicado: (2018)

Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
por: Wells, J Connor, et al.
Publicado: (2022)

Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
por: Nakamura, Ikuo, et al.
Publicado: (2014)

Serum metabolomic profile as a means to distinguish stage of colorectal cancer
por: Farshidfar, Farshad, et al.
Publicado: (2012)

Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
por: Nakamura, Ikuo, et al.
Publicado: (2015)

Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report
por: Zhu, Hong, et al.
Publicado: (2019)

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis
por: Morgen, Eric K, et al.
Publicado: (2017)

Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
por: Boutin, Mélina, et al.
Publicado: (2023)

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
por: Garrett, C R, et al.
Publicado: (2011)

Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions
por: Deng, Yangqing, et al.
Publicado: (2023)

Meeting Report from “Frontiers in Nutritional Science: Nutritional Metabolomics”
por: O’Callaghan, Nathan, et al.
Publicado: (2014)

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
por: Hoch, Jeffrey S., et al.
Publicado: (2019)

Identification of prognostic inflammatory factors in colorectal liver metastases
por: Hamilton, Trevor D, et al.
Publicado: (2014)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Renouf, Daniel J., et al.
Publicado: (2022)

Serum Metabolomics of Activity Energy Expenditure and its Relation to Metabolic Syndrome and Obesity
por: Palmnäs, Marie S. A., et al.
Publicado: (2018)

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
por: Fontana, Elisa, et al.
Publicado: (2020)

Comparison of Two Automated Targeted Metabolomics Programs to Manual Profiling by an Experienced Spectroscopist for (1)H-NMR Spectra
por: Wang, Xiangyu, et al.
Publicado: (2022)

Systematic Review of Vitamin D and Hypertensive Disorders of Pregnancy
por: O’Callaghan, Karen M., et al.
Publicado: (2018)

Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of (1)H-NMR Spectroscopy and Gas Chromatography–Mass Spectrometry
por: McConnell, Yarrow J., et al.
Publicado: (2017)

The effectiveness of a specialist Hypertension Clinic in reducing blood pressure: Factors determining blood pressure response
por: O’Callaghan, Georgina, et al.
Publicado: (2020)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Performance of variable selection methods using stability-based selection
por: Lu, Danny, et al.
Publicado: (2017)

The effect of halothane and pentobarbital sodium on brain ependymal cilia
por: O’Callaghan, Chris, et al.
Publicado: (2012)

From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer
por: Bathe, Oliver F., et al.
Publicado: (2014)

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
por: Kennecke, Hagen F., et al.
Publicado: (2023)

The Pathogenesis of Staphylococcus aureus Eye Infections
por: O’Callaghan, Richard J.
Publicado: (2018)

Characteristics of chronic thromboembolic pulmonary hypertension in Ireland
por: Cullivan, Sarah, et al.
Publicado: (2021)

Pasture Feeding Changes the Bovine Rumen and Milk Metabolome
por: O’Callaghan, Tom F., et al.
Publicado: (2018)

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
por: Chen, Eric X., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bkkr7gdbu118gns6m8g38anr9o